Post-marketing safety concerns with elagolix: a disproportionality analysis of the FDA adverse event reporting system
CONCLUSION: Our study provides a comprehensive picture of the safety of elagolix in the post-marketing setting, while also identifying potential new AE signals. These findings emphasize the importance of continued monitoring of the potential risks of elagolix.PMID:38700323 | DOI:10.1080/14740338.2024.2351451
Source: Expert Opinion on Drug Safety - Category: Drugs & Pharmacology Authors: En Chang Yong-Fang Shi Jin-Feng Liu Wei Wei Source Type: research
More News: Clinical Trials | Cystitis | Depression | Drugs & Pharmacology | Endometriosis | Liver | Men | Pain | Study | Suicide | Urology & Nephrology